Posters/Publications

TitleVenue TypeDate
Heavily Pre-Treated Breast Cancer Patients show Promising Responses in the First in Human Study of the First-In-Class Fatty Acid Synthase (FASN) Inhibitor, TVB-2640 in Combination with Paclitaxel

European Society for Medical Oncology (ESMO) Congress

oral09/2020
Novel, first-in-class, fatty acid synthase inhibitor, TVB-2640 versus placebo demonstrates clinically significant reduction in liver fat by MRI-PDFF in NASH

EASL International Liver Congress

oral08/2020
The FASN inhibitor TVB-2640 is efficacious in a new 3D human liver microtissue model of NASH

EASL International Liver Congress

poster08/2020
Fatty Acid Synthase Inhibitor TVB-2640 Reduces Hepatic de Novo Lipogenesis in Males With Metabolic Abnormalities

Hepatology 2020

paper07/2020
Updated Results from a Prospective Phase 2 Study in Patients with First Relapse of High-grade Astrocytoma Using TVB-2640 in Combination with bevacizumab

ASCO

poster06/2019
FASN inhibition as a potential treatment for therapy of endocrine resistant breast cancer

San Antonio Breast Cancer Symposium

poster12/2018
Fibroblast Growth Factor-21 and its Relationship to Human Liver Fat Synthesis; Impact of a New Therapeutic Agent

ObesityWeek

poster11/2018
The FASN inhibitor, TVB3664, Ameliorates NASH in a Murine Model

AASLD

poster11/2018
Updated results from a prospective, randomized phase 2 study in patients with first relapse of high-grade astrocytoma using TVB-2640 in combination with Avastin versus Avastin alone

Annual Scientific Meeting and Education Day of the Society for Neuro-Oncology

poster11/2018
Progressive Reductions in Hepatic DNL with Increasing Doses of TVB-2640, a First-in-Class Pharmacologic Inhibitor of FASN

Keystone Symposium on Organ Crosstalk in Obesity and NAFLD

poster01/2018
Fatty acid synthase inhibitor TVB-3664 reverses multiple components of diet-induced nonalcoholic steatohepatitis in mice treated with or without co-administered pirfenidone and reduces collagen accumulation in bleomycin-induced murine skin fibrosis

AASLD

poster10/2017
Pharmacologic Inhibition of FASN Reverses Diet-Induced Steatohepatitis in Mice and Inhibits Lipogenesis in Humans.

AASLD

poster10/2017
First in human study of the first-in-class fatty acid synthase (FASN) inhibitor TVB-2640

AACR Annual Meeting

oral04/2017
Establishing the foundation for a novel, first-in-class, fatty acid synthase inhibitor, TVB-2640, for the treatment of NASH

EASL International Liver Congress

poster04/2017
Fatty Acid Synthase – Modern Tumor Cell Biology Insights into a Classical Oncology Target

Pharmacology and Therapeutics

paper02/2017
Heavily Pre-Treated Breast Cancer Patients show Promising Responses in the First in Human Study of the First-In-Class Fatty Acid Synthase (FASN) Inhibitor, TVB-2640 in Combination with Paclitaxel

San Antonio Breast Cancer Symposium

poster12/2016
FASN inhibition and taxane treatment combine to enhance anti-tumor efficacy in diverse xenograft tumor models through disruption of tubulin palmitoylation and microtubule organization and FASN inhibition-mediated effects on oncogenic signaling and gene expression

EBioMedicine

paper12/2016
Pharmacological inhibition of FASN Prevents High Fat Diet Induced Liver Damage in Mice and Significantly Reduces de novo Lipogenesis in Humans

AASLD The Liver Meeting

poster11/2016
Preliminary Activity in the First in Human Study of the First-In-Class Fatty Acid Synthase Inhibitor, TVB-2640

NCRI Cancer Conference

poster11/2016
Mechanism and rationale for inhibition of FASN as a novel therapy for KRAS-mutant non-small cell lung cancer patients

Precison: Lung Cancer R&D Summit

oral09/2016
DeNovo Palmitate Synthesis Supports Oncogenic Signaling Through Diverse Mechanisms: Implications for FASN-Targeted Therapeutics

Journal of Cell Signaling

paper08/2016
Preliminary Activity in the First in Human Study of the First-In-Class Fatty Acid Synthase (FASN) Inhibitor, TVB-2640

ASCO Annual Meeting

poster06/2016
FASN inhibitor TVB-2640 shows pharmacodynamic effect and evidence of clinical activity in KRAS mutant NSCLC patients in a Phase 1 study

AACR Annual Meeting

poster04/2016
Preclinical studies characterize tumor type sensitivity to FASN inhibition and the mechanism and efficacy of novel drug combinations with TVB-2640

AACR Annual Meeting

poster04/2016
Preliminary Activity in the First in Human Study of the First-In-Class Fatty Acid Synthase (FASN) Inhibitor, TVB-2640

International Congress on Targeted Anticancer Therapies

oral03/2016
Sebum Analysis from Dose Escalation and Expansion Phases of the FASN Inhibitor TVB-2640 Phase 1 Trial, A Non-Invasive Biomarker of Target Engagement

Keystone Symposium – New Frontiers in Understanding Tumor Metabolism

poster02/2016
Sebum Analysis from Dose Escalation and Expansion Phases of the FASN Inhibitor TVB-2640 Phase 1 Trial, A Non-Invasive Biomarker of Target Engagement

Keystone Symposium – New Frontiers in Understanding Tumor Metabolism

oral02/2016
Direct Inhibition of Cellular Fatty Acid Synthase Impairs Replication of Respiratory Synctial Virus and Other Respiratory Viruses

PLOS ONE

paper12/2015
A First in Human Study of the First in Class Fatty Acid Synthase (FASN) Inhibitor TVB-2640. Results of Dose Escalation in Mono and Combination and Evidence of Preliminary Activity

EORTC-NCI-AACR International Conference

poster11/2015
Biomarker Analyses from Dose Escalation and Expansion Phases of FASN Inhibitor TVB-2640 Phase 1 Study Shows Target Engagement in Solid Tumor Patients

EORTC-NCI-AACR International Conference

poster11/2015
FASN inhibition studies in preclinical tumor models identify biomarkers that align with in vitro and in vivo sensitivity to TVB-2640

EORTC-NCI-AACR International Conference

poster11/2015
Biomarker Analyses from Dose Escalation Phase of FASN Inhibitor TVB-2640 Phase 1 Study Shows Target Engagement in Solid Tumor Patients

EORTC-NCI-AACR International Conference

poster11/2015
Inhibition of de novo Palmitate Synthesis by Fatty Acid Synthase Induces Apoptosis in Tumor Cells by Remodeling Cell Membranes, Inhibiting Signaling Pathways, and Reprogramming Gene Expression

EBioMedicine

paper07/2015
Translational Studies of a First-in-class FASN Inhibitor, TVB-2640, Linking Preclinical Studies to Clinical Laboratory Observations in Solid Tumor Patients

AACR Special Conference: Metabolism and Cancer

poster06/2015
First-in-Human Investigation of the Oral First-in-Class Fatty Acid Synthase (FASN) Inhibitor, TVB-2640

ASCO Annual Meeting

poster06/2015
Diacylglycerol Metabolism and Signaling Is a Driving Force Underlying FASN Inhibitor Sensitivity in Cancer Cells

ACS Chemical Biology

paper04/2015
Discovery of tumor types highly susceptible to FASN inhibition and biomarker candidates for clinical analysis

AACR Annual Meeting

poster04/2015
Biomarker and PK/PD analyses of first-in-class FASN inhibitor TVB-2640 in a first-in-human phase 1 study in solid tumor patients

AACR Annual Meeting

poster04/2015
Report of a First-In-Human Study of the First-In-Class Fatty Acid Synthase (FASN) Inhibitor, TVB-2640

AACR Annual Meeting

poster04/2015
Initial report of a first-in-human study of the first-in-class fatty acid synthase (FASN) inhibitor, TVB-2640

EORTC-NCI-AACR International Conference

oral11/2014
Mechanistic analysis of reversible FASN inhibition in preclinical tumor models identifies highly susceptible tumor types and enriches biomarker discovery for clinical applications

EORTC-NCI-AACR International Conference

poster11/2014
Efficacy of FASN-selective small molecule inhibitors of preclinical tumor models

AACR Annual Meeting

poster04/2014
Inhibition of Fatty Acid Synthase in vitro and in vivo Reduces RSV Replication

Keystone Meeting – Pathogenesis of Respiratory Viruses

poster01/2014
Characterization of small-molecule FASN inhibitors in preclinical tumor models

AACR-NCI-EORTC International Conference

poster10/2013
Imidazopyridine-Based Fatty Acid Syhthase Inhibitors That Show Anti-HCV Activity and in Vivo Target Modulation

ACS Medicinal Chemistry Letters

paper12/2012
Potent HCV Antiviral Activity by Inhibiting Fatty Acid Synthase

AASLD The Liver Meeting

oral11/2012
A Novel, Host-Directed Small Molecule Inhibitor of HCV Displays Sustained Pharmacological Inhibition of Liver Fatty Acid Synthase

AASLD The Liver Meeting

poster11/2012
TitleVenue TypeDate
Heavily Pre-Treated Breast Cancer Patients show Promising Responses in the First in Human Study of the First-In-Class Fatty Acid Synthase (FASN) Inhibitor, TVB-2640 in Combination with Paclitaxel

European Society for Medical Oncology (ESMO) Congress

oral09/2020
Updated Results from a Prospective Phase 2 Study in Patients with First Relapse of High-grade Astrocytoma Using TVB-2640 in Combination with bevacizumab

ASCO

poster06/2019
FASN inhibition as a potential treatment for therapy of endocrine resistant breast cancer

San Antonio Breast Cancer Symposium

poster12/2018
Updated results from a prospective, randomized phase 2 study in patients with first relapse of high-grade astrocytoma using TVB-2640 in combination with Avastin versus Avastin alone

Annual Scientific Meeting and Education Day of the Society for Neuro-Oncology

poster11/2018
Fatty acid synthase inhibitor TVB-3664 reverses multiple components of diet-induced nonalcoholic steatohepatitis in mice treated with or without co-administered pirfenidone and reduces collagen accumulation in bleomycin-induced murine skin fibrosis

AASLD

poster10/2017
First in human study of the first-in-class fatty acid synthase (FASN) inhibitor TVB-2640

AACR Annual Meeting

oral04/2017
Fatty Acid Synthase – Modern Tumor Cell Biology Insights into a Classical Oncology Target

Pharmacology and Therapeutics

paper02/2017
Heavily Pre-Treated Breast Cancer Patients show Promising Responses in the First in Human Study of the First-In-Class Fatty Acid Synthase (FASN) Inhibitor, TVB-2640 in Combination with Paclitaxel

San Antonio Breast Cancer Symposium

poster12/2016
FASN inhibition and taxane treatment combine to enhance anti-tumor efficacy in diverse xenograft tumor models through disruption of tubulin palmitoylation and microtubule organization and FASN inhibition-mediated effects on oncogenic signaling and gene expression

EBioMedicine

paper12/2016
Preliminary Activity in the First in Human Study of the First-In-Class Fatty Acid Synthase Inhibitor, TVB-2640

NCRI Cancer Conference

poster11/2016
Mechanism and rationale for inhibition of FASN as a novel therapy for KRAS-mutant non-small cell lung cancer patients

Precison: Lung Cancer R&D Summit

oral09/2016
DeNovo Palmitate Synthesis Supports Oncogenic Signaling Through Diverse Mechanisms: Implications for FASN-Targeted Therapeutics

Journal of Cell Signaling

paper08/2016
Preliminary Activity in the First in Human Study of the First-In-Class Fatty Acid Synthase (FASN) Inhibitor, TVB-2640

ASCO Annual Meeting

poster06/2016
FASN inhibitor TVB-2640 shows pharmacodynamic effect and evidence of clinical activity in KRAS mutant NSCLC patients in a Phase 1 study

AACR Annual Meeting

poster04/2016
Preclinical studies characterize tumor type sensitivity to FASN inhibition and the mechanism and efficacy of novel drug combinations with TVB-2640

AACR Annual Meeting

poster04/2016
Preliminary Activity in the First in Human Study of the First-In-Class Fatty Acid Synthase (FASN) Inhibitor, TVB-2640

International Congress on Targeted Anticancer Therapies

oral03/2016
Sebum Analysis from Dose Escalation and Expansion Phases of the FASN Inhibitor TVB-2640 Phase 1 Trial, A Non-Invasive Biomarker of Target Engagement

Keystone Symposium – New Frontiers in Understanding Tumor Metabolism

poster02/2016
Sebum Analysis from Dose Escalation and Expansion Phases of the FASN Inhibitor TVB-2640 Phase 1 Trial, A Non-Invasive Biomarker of Target Engagement

Keystone Symposium – New Frontiers in Understanding Tumor Metabolism

oral02/2016
A First in Human Study of the First in Class Fatty Acid Synthase (FASN) Inhibitor TVB-2640. Results of Dose Escalation in Mono and Combination and Evidence of Preliminary Activity

EORTC-NCI-AACR International Conference

poster11/2015
Biomarker Analyses from Dose Escalation and Expansion Phases of FASN Inhibitor TVB-2640 Phase 1 Study Shows Target Engagement in Solid Tumor Patients

EORTC-NCI-AACR International Conference

poster11/2015
FASN inhibition studies in preclinical tumor models identify biomarkers that align with in vitro and in vivo sensitivity to TVB-2640

EORTC-NCI-AACR International Conference

poster11/2015
Biomarker Analyses from Dose Escalation Phase of FASN Inhibitor TVB-2640 Phase 1 Study Shows Target Engagement in Solid Tumor Patients

EORTC-NCI-AACR International Conference

poster11/2015
Inhibition of de novo Palmitate Synthesis by Fatty Acid Synthase Induces Apoptosis in Tumor Cells by Remodeling Cell Membranes, Inhibiting Signaling Pathways, and Reprogramming Gene Expression

EBioMedicine

paper07/2015
Translational Studies of a First-in-class FASN Inhibitor, TVB-2640, Linking Preclinical Studies to Clinical Laboratory Observations in Solid Tumor Patients

AACR Special Conference: Metabolism and Cancer

poster06/2015
First-in-Human Investigation of the Oral First-in-Class Fatty Acid Synthase (FASN) Inhibitor, TVB-2640

ASCO Annual Meeting

poster06/2015
Diacylglycerol Metabolism and Signaling Is a Driving Force Underlying FASN Inhibitor Sensitivity in Cancer Cells

ACS Chemical Biology

paper04/2015
Discovery of tumor types highly susceptible to FASN inhibition and biomarker candidates for clinical analysis

AACR Annual Meeting

poster04/2015
Biomarker and PK/PD analyses of first-in-class FASN inhibitor TVB-2640 in a first-in-human phase 1 study in solid tumor patients

AACR Annual Meeting

poster04/2015
Report of a First-In-Human Study of the First-In-Class Fatty Acid Synthase (FASN) Inhibitor, TVB-2640

AACR Annual Meeting

poster04/2015
Initial report of a first-in-human study of the first-in-class fatty acid synthase (FASN) inhibitor, TVB-2640

EORTC-NCI-AACR International Conference

oral11/2014
Mechanistic analysis of reversible FASN inhibition in preclinical tumor models identifies highly susceptible tumor types and enriches biomarker discovery for clinical applications

EORTC-NCI-AACR International Conference

poster11/2014
Efficacy of FASN-selective small molecule inhibitors of preclinical tumor models

AACR Annual Meeting

poster04/2014
Characterization of small-molecule FASN inhibitors in preclinical tumor models

AACR-NCI-EORTC International Conference

poster10/2013